FOGHORN THERAPEUTICS INC. (FHTX) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - FOGHORN THERAPEUTICS INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, capex, opex, cash flow, tax rate, share count, dividends, or buybacks) provided.
• Cash runway extended through the second half of 2029, following restructuring in October, providing sufficient capital to complete the first-in-human Single Ascending Dose and Multiple Ascending Dose (SADMAD) studies with approximately one year of cash remaining thereafter.

Business-Segment Outlook:

• Oncology (Hematological Malignancies): The EP300 program for multiple myeloma and potentially diffuse large B-cell lymphoma (DLBCL) is on track for an IND by the end of 2027. The program utilizes a once-a-week subcutaneous formulation with backup oral delivery efforts. It is positioned for second, third, or fourth-line settings as an orthogonal mechanism to existing therapies (CD38, BCMA, IMIDs, proteasome inhibitors).
• Oncology (Solid Tumors): The CBP program targeting ER-positive breast cancer is paused due to CRO facility loss; resumption of in vivo work and dose projections is targeted for the first half of next year to support a "go/no-go" decision. The program aims for a once-a-week long-acting injectable.
• Non-Oncology (Inflammatory Bowel Disease): The INI program targeting ulcerative colitis and Crohn's disease is in preclinical development. Non-GLP toxicology studies (rat and dog) are scheduled to begin in December. First-in-human studies are targeted to start before the end of 2027.
• Pipeline Timing: Goal to generate safety and disease activity data (SADMAD package and early patient data) for the INI program in the second half of 2028, specifically the Q3 timeframe.
• Induced Proximity Platform: Aiming to disclose in vitro proof of concept for degrading secreted cytokines (e.g., IL-12, IL-23, TNF-alpha) and transmembrane proteins in the first half of next year, with potential business development activity targeted for 2027.

Market and Competitive Outlook:

• Multiple Myeloma: Management views the disease as increasingly chronic rather than curable, suggesting an expanding patient population suitable for later-line therapies. While acknowledging strong data from competitors (e.g., J&J), management sees a clear opportunity for an orthogonal EP300-selective mechanism to address relapse, particularly when combined with existing cytopenia-inducing agents.
• Selectivity Advantage: Management anticipates that high selectivity (100-fold to 10,000-fold) over CBP for their EP300 degrader offers a competitive edge by eliminating platelet impacts (thrombocytopenia) associated with dual CBP-EP300 targeting by peers (e.g., Cellcentric).
• Target Differentiation: The INI program targets a target for which, based on public domain data, no other competitors are currently active in the IBD space (Ulcerative Colitis/Crohn's), with preclinical data comparable to the murine version of an IL-12/23 antibody.
• Peer Validation: Positive sentiment regarding the validation of dual CBP-EP300 targets by Cellcentric, though management expects the industry to continue monitoring data as the space matures.

Macro / Industry Outlook:

• Therapeutic Shifts: Acknowledges a structural shift away from "synthetic lethality" and chromatin remodeling complexes (BAF complex) in oncology toward targets demonstrating clear frank dependency, citing the SMARCA2/FHD909 program failure as evidence of flawed biological understanding in the previous approach.
• Platform Evolution: The company is pivoting from protein degradation to "induced proximity" and leveraging the endoplasmic reticulum (ER) to degrade secreted and transmembrane proteins, a capability seen as highly open for partnering.
• Collaboration Landscape: Anticipates that the industry will continue to validate the dual CBP-EP300 approach, but notes that capital allocation for such targets may be skeptical unless selectivity issues (like those in the SMARCA2 program) are resolved.

Strategic Initiatives:

• M&A / Partnerships:
  • EP300: High likelihood of seeking a strategic partner prior to or early in clinical development due to the competitive nature of the multiple myeloma space and the need for complex combination studies.
  • Induced Proximity: Actively exploring partnership opportunities for the ER-targeting platform, with conversations already held with several pharmaceutical companies.
  • CBP: Potential for a "go/no-go" decision in the first half of next year, followed by potential financing or partnership if selected for advancement.
• Restructuring: Completed restructuring in October to extend cash runway and optimize the pipeline focus.
• Molecule Optimization: Developing a mix of chemistry and engineering to achieve specific selectivity thresholds (potentially 100-fold) to mitigate safety issues like thrombocytopenia.

Risks and Headwinds to Outlook:

• Clinical Failure Risk: The failure of the SMARCA2 program is attributed to flawed biological understanding rather than molecule efficacy; similar skepticism exists for other programs targeting the same biology.
• Delays: The CBP program faced a delay due to a CRO losing its animal facility, requiring a return to preclinical work and new in vivo models.
• Development Uncertainty: The timing of first-in-human studies (end of 2027) and potential partnership deals are contingent on successful preclinical toxicology and proof-of-concept data.
• Competitive Landscape: While the INI target is currently unique, the multiple myeloma space remains highly competitive with established sequencing mechanisms (CD38, BCMA, etc.).
• Biological Translation: Preclinical excitement does not guarantee clinical translation, as evidenced by the disconnect between preclinical data and clinical outcomes in the SMARCA2 program.

Management Tone on the Future:

• Cautiously Optimistic: Tone reflects a strategic pivot following the discontinuation of the FHD909 program. Management expresses confidence in the platform's ability to target "challenging" proteins and the specific advantages of their selective EP300 degrader.
• Pragmatic: Acknowledges the need to validate the CBP program further before committing resources and maintains a "wait and see" approach on the INI and induced proximity platforms until specific data readouts.
• Forward-Looking: Emphasizes the evolution of the company's capabilities from chromatin remodeling to broader protein degradation and induced proximity, viewing this as a new chapter rather than a limitation.

Miscellaneous:

• SMARCA2 Insight: Management stated they are "very skeptical" about allocating capital to the SMARCA2 target in the future, noting that even high-potency degraders required >95% degradation to match inhibitor efficacy, suggesting the biology itself may be flawed.
• Data Disclosure: Additional cytokine impact and detailed safety data for the INI program are expected to be released in the first half of the upcoming year.